Ramipril in the treatment of vascular diseases.
Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardiovascular death, myocardial infarction, stroke, congestive heart failure, progressive renal impairment and onset of diabetes. Ramipril is usually dosed at 2.5-10 mg/day. Beneficial effects of ramipril are observed in the treatment of hypertension and congestive heart failure, prevention of cardiovascular events in high-risk patients, prevention of congestive heart failure, diabetes and other vascular events.
Rokoss
Michael J
MJ
Division of Cardiology, McMaster University, Room 3U4 McMaster University Medical Centre, Hamilton, Ontario, L8N 3Z5, Canada. rokossm@mcmaster.ca
Teo
Koon K
KK
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D002339:Carotid Arteries / Q000187:drug effects / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D011507:Proteinuria / Q000517:prevention & control; D017257:Ramipril / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D051437:Renal Insufficiency / Q000188:drug therapy / Q000517:prevention & control; D014018:Tissue Distribution
D000806:Angiotensin-Converting Enzyme Inhibitors; D017257:Ramipril